Abstract
Pancreatic cancer (PC) is associated with a poor prognosis, primarily due to challenges in the early diagnosis of resectable tumours. Screening at-risk patients for PC-specific circulating molecular biomarkers is potentially an optimal method of earlier detection. Currently, CA19-9 is the only clinically applied marker. However, this non-specific marker’s early PC diagnostic capabilities are insufficient. Circulating exosomes are unique as they possess numerous molecules derived from their originating cell.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call